Cingulate

Cingulate Accounts Payable

The Accounts Payable of Cingulate (CING) as of Nov 11, 2026 is 2.04 M USD. In the previous year, Accounts Payable was 1.27 M USD — a change of 60.25% (higher).

Accounts Payable

2.04 MUSD

YoY

60.25%

Last updated:

Accounts Payable of Cingulate is 2025 2.04 M USD. Accounts Payable of Cingulate was 2024 1.27 M USD. It decreases by 60.25% higher compared to the previous year.

The Cingulate Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
1.90 M USD
Jan 1, 2020
975,114.00 USD
Jan 1, 2021
264,687.00 USD
Jan 1, 2022
762,357.00 USD
Jan 1, 2023
5.20 M USD
Jan 1, 2024
1.27 M USD
Jan 1, 2025
2.04 M USD
The Cingulate Accounts Payable history
YEARAccounts PayableYoY
2.04 MUSD+60.25%
1.27 MUSD-75.57%
5.20 MUSD+581.98%
762,357.00USD+188.02%
264,687.00USD-72.86%
975,114.00USD-48.57%
1.90 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Accounts Payable of Cingulate is 2.04 M USD in 2025.

Accounts Payable of Cingulate changed from 1.27 M USD to 2.04 M USD, representing a 60.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Cingulate since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cingulate

All Key Metrics — Cingulate